Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Castle Biosciences, Inc. - SIC # 8071 - MEDICAL LABORATORIES
Ticker
Exchange
SIC #
Website
Latest Ticker
CSTL
Nasdaq
8071
castlebiosciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Castle Biosciences, Inc.
Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors
- Nov 19th, 2026 6:30 am
Castle Biosciences (CSTL) Stock Could Be Undervalued Following Raised 2026 Guidance
- Nov 13th, 2026 10:17 pm
Castle Biosciences (CSTL) Lifts Guidance Following Revenue Growth But Is The Valuation Already Priced In
- Nov 12th, 2026 6:15 pm
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
- Nov 12th, 2026 5:00 am
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
- Nov 11th, 2026 2:30 pm
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
- Nov 11th, 2026 5:00 am
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade
- Nov 10th, 2026 6:55 am
Castle Biosciences Stock Gets A Lift From Raised 2026 Outlook
- Nov 6th, 2026 11:19 am
Castle Biosciences, Inc. Q3 2026 Earnings Call Summary
- Nov 6th, 2026 6:30 am
Castle Biosciences Inc (CSTL) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...
- Nov 6th, 2026 4:17 am
What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call
- Nov 5th, 2026 8:14 pm
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates
- Nov 5th, 2026 2:45 pm
Castle Biosciences Reports Third Quarter 2026 Results
- Nov 5th, 2026 2:05 pm
Castle Biosciences to Participate in Upcoming Investor Conferences
- Oct 28th, 2026 5:00 am
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
- Oct 15th, 2026 5:00 am
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
- Oct 12th, 2026 2:30 pm
New Melanoma Study Backing DecisionDx-Melanoma Could Be A Game Changer For Castle Biosciences (CSTL)
- Oct 8th, 2026 11:15 pm
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
- Sep 30th, 2026 2:30 pm
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
- Sep 28th, 2026 5:00 am
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
- Sep 24th, 2026 2:30 pm
Scroll